Cubist Systematic Strategies, LLC Atai Life Sciences N.V. Transaction History

Cubist Systematic Strategies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.04 - $1.55 $4,922 - $7,336	-4,733 Reduced 11.54%	36,288 $51,000
Q3 2023 Nov 14, 2023	BUY	$1.27 - $2.28 $38,540 - $69,191	30,347 Added 284.31%	41,021 $52,000
Q2 2023 Aug 14, 2023	SELL	$1.44 - $2.19 $42,583 - $64,762	-29,572 Reduced 73.48%	10,674 $18,000
Q1 2023 May 15, 2023	SELL	$1.17 - $2.7 $237,046 - $547,030	-202,604 Reduced 83.43%	40,246 $72,000
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $332,616 - $496,130	139,755 Added 135.56%	242,850 $645,000
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $98,577 - $152,888	31,394 Added 43.78%	103,095 $341,000
Q2 2022 Aug 15, 2022	BUY	$3.03 - $5.32 $21,085 - $37,021	6,959 Added 10.75%	71,701 $261,000
Q1 2022 May 16, 2022	SELL	$4.66 - $7.66 $22,820 - $37,511	-4,897 Reduced 7.03%	64,742 $330,000
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $284,878 - $743,523	41,771 Added 149.89%	69,639 $531,000
Q3 2021 Nov 15, 2021	BUY	$13.62 - $19.48 $379,562 - $542,868	27,868 New	27,868 $412,000

12.4M

77.8K

50.3K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $197M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.